Hearps AC, Angelovich TA, Trevillyan JM, et al. - Given that in people with HIV (PWH) with chronic inflammation due to their pleotropic lipid lowering and anti-inflammatory properties, statins may aid in averting cardiovascular disease (CVD). In this double-blind, placebo-controlled trial, researchers sought to determine how 48 weeks of rosuvastatin therapy affects inflammation and immune activation in PWH at moderate CVD risk. No alteration in plasma levels of IL-6, soluble (s)TNF-RII, CXCL10, sCD14 or sVCAM-1 was noted in correlation with providing rosuvastatin. PWH receiving rosuvastatin showed increased proportions of CD16 + monocyte subsets. These findings suggest that further clinical outcome research is required to determine the potential benefits of statin use in PWH with normal lipid levels.